Orchestra BioMed Holdings, Inc.

NASDAQ:OBIO

Biotechnology

Healthcare
$7.46 +1.16%

+$0.05 today

Market cap
$587.14M
Beta
0.50
P/E (TTM)
-2.8
EPS (TTM)
-$1.42
52W Low $2.20High $5.42

Volume 1.20M

Average 0.22M

Returns on capital

Orchestra BioMed Holdings, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-83.2%

avg -54.7%

ROIC

-52.4%

avg -165.4%

ROA

-45.9%

avg -73.2%

Analysis

ROA is currently the strongest return metric at -45.9% versus its period average of -73.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

David Hochman

Founder, Chairman of the Board of Directors & Chief Executive OfficerUSD 1.18M51——

Darren R. Sherman

Founder, President, Chief Operating Officer & DirectorUSD 1.04M55——

Andrew Lawrence Taylor

Chief Financial OfficerUSD 766.68K55590.99K0.99%

Yuval Hay Mika D.Sc

GM & Chief Technology Officer of Bioelectronic Therapies—67——

Bob Laughner

Senior Vice President of Regulatory & Quality————

William Reed Little

Executive Vice President of Corporate Development & Strategy—55307.86K0.51%

Avraham Matityahu Fischer

Senior Vice President of Medical Affairs & Innovation—70——

Hans-Peter Stoll

Senior Vice President & Medical Director————

Juan Lorenzo

Senior Vice President of Product Development————

Lisa Daniels

Vice President of Human Resources————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 9, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

13

$6.49M

Sells

7

$439,182.16

Net Transaction Value

+$6.05M

Net buying

Most Active

Sherman Darren

7 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Nov 9, 26

RTW INVESTMENTS, LP

Indirect

Buy$6M
Nov 9, 26

Fain Eric S

Indirect

Buy$100K
Nov 9, 26

Pacitti David

Direct

Buy$100K
Nov 9, 26

Hochman David P

Indirect

Buy$25K
Nov 9, 26

Taylor Andrew Lawrence

Direct

Buy$5K
Nov 2, 26

Sherman Darren

Direct

Sell$86.1K
Oct 1, 26

Sherman Darren

Direct

Sell$95.4K
Sep 3, 26

Hochman David P

Direct

Buy$47.9K
Sep 1, 26

Sherman Darren

Direct

Sell$74.1K
Aug 26, 26

Sherman Darren

Indirect

Buy$10.7K

1–10 of 20

Summary

Insiders reported 13 buys worth $6.49M and 7 sells worth $439,182.16 over the last 12 months. That adds up to net buying of $6.05M. Sherman Darren was the most active insider with 7 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/A+111.6%
+25.5% (5yr)2 analysts
Net IncomeN/AN/AN/A
N/A2 analysts
EBITN/AN/AN/A
N/A2 analysts

Analysis

Recent growth has been strongest in Revenue at +111.6% over three years. Forward estimates point to Revenue at +25.5% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Orchestra BioMed Holdings, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about OBIO's management, answered from reported figures.

Who manages OBIO?

Orchestra BioMed Holdings, Inc. (OBIO) lists 10 active executives. The top listed executive is Yuval Hay Mika D.Sc, GM & Chief Technology Officer of Bioelectronic Therapies.

Are OBIO insiders buying or selling?

Recent insider activity shows net buying of $11.99M.